Versant Capital Management Inc Boosts Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Versant Capital Management Inc increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 1,324.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,336 shares of the medical research company's stock after purchasing an additional 2,172 shares during the period. Versant Capital Management Inc's holdings in Charles River Laboratories International were worth $352,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in CRL. First Hawaiian Bank lifted its holdings in shares of Charles River Laboratories International by 13.9% during the first quarter. First Hawaiian Bank now owns 5,096 shares of the medical research company's stock worth $767,000 after buying an additional 620 shares in the last quarter. Kera Capital Partners Inc. increased its position in Charles River Laboratories International by 42.6% during the first quarter. Kera Capital Partners Inc. now owns 1,900 shares of the medical research company's stock worth $286,000 after acquiring an additional 568 shares during the period. Confluence Investment Management LLC raised its stake in Charles River Laboratories International by 3.8% in the 1st quarter. Confluence Investment Management LLC now owns 96,526 shares of the medical research company's stock worth $14,529,000 after purchasing an additional 3,522 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in Charles River Laboratories International by 29.8% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,411 shares of the medical research company's stock valued at $212,000 after purchasing an additional 324 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of Charles River Laboratories International by 3.2% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,970 shares of the medical research company's stock worth $1,102,000 after purchasing an additional 187 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president now owns 19,513 shares in the company, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and increased their price target for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target on the stock in a research note on Wednesday, May 14th. Morgan Stanley cut their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. Finally, Robert W. Baird upped their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International has an average rating of "Hold" and an average target price of $171.85.

Charles River Laboratories International Stock Up 3.7%

Shares of NYSE CRL traded up $5.18 during mid-day trading on Wednesday, reaching $143.67. 352,395 shares of the company's stock traded hands, compared to its average volume of 991,601. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The business has a 50-day simple moving average of $128.17 and a 200 day simple moving average of $159.66. The stock has a market cap of $7.06 billion, a P/E ratio of 957.80, a PEG ratio of 4.54 and a beta of 1.48. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same quarter in the previous year, the business earned $2.27 EPS. The company's quarterly revenue was down 2.7% on a year-over-year basis. On average, analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).